hormonal replacement therapy

Description Results NMA

all cause death 1.40 [0.50; 3.89]

Coronary events (CHD) 0.90 [0.59; 1.35]

Cv death 1.40 [0.32; 6.10]

non fatal MI 0.90 [0.31; 2.59]

stroke 0.88 [0.28; 2.78]

CV events 0.98 [0.51; 1.88]

venous thromboembolism 5.25 [0.62; 44.16]

all cause death 1.78 [0.76; 4.14]

Cv death 1.35 [0.48; 3.83]

non fatal MI 2.28 [0.71; 7.30]

stroke 1.76 [0.96; 3.22]

CV events 0.92 [0.67; 1.28]

venous thromboembolism 1.01 [0.26; 4.00]

all cause death 0.50 [0.09; 2.65]

CV events 1.00 [0.54; 1.85]

CV events 1.55 [1.02; 2.36]

all cause death 0.54 [0.10; 2.78]

venous thromboembolism 26.29 [15.18; 45.51]

all cause death 1.06 [0.84; 1.34]

Coronary events (CHD) 0.98 [0.80; 1.19]

Cv death 1.19 [0.85; 1.67]

non fatal MI 0.91 [0.72; 1.15]

stroke 1.11 [0.85; 1.44]

CV events 0.99 [0.90; 1.10]

PE 2.76 [0.88; 8.63]

all cause death 0.00 [0.00; NaN]

Cv death 0.00 [0.00; NaN]

non fatal MI 1.00 [0.06; 15.79]

stroke ∞ [NaN; ∞]

CV events 1.50 [0.26; 8.80]

venous thromboembolism 7.77 [1.00; 60.53]

PE 2.92 [0.31; 27.35]

all cause death 0.00 [0.00; NaN]

Cv death ∞ [NaN; ∞]

stroke ∞ [NaN; ∞]

CV events 0.75 [0.24; 2.36]

all cause death 0.81 [0.51; 1.27]

Coronary events (CHD) 1.00 [0.72; 1.39]

Cv death 0.69 [0.40; 1.18]

non fatal MI 1.30 [0.83; 2.04]

stroke 1.64 [0.60; 4.47]

venous thromboembolism 1.96 [0.18; 21.60]

PE 0.98 [0.20; 4.84]

all cause death 1.14 [0.77; 1.67]

Cv death 0.82 [0.37; 1.81]

non fatal MI 1.13 [0.53; 2.41]

stroke 1.09 [0.79; 1.51]

CV events 0.79 [0.62; 1.00]

venous thromboembolism 0.73 [0.16; 3.23]

PE 0.97 [0.14; 6.85]

Coronary events (CHD) 1.28 [1.01; 1.62]

non fatal MI 1.32 [1.02; 1.71]

stroke 1.42 [1.08; 1.87]

CV events 1.19 [1.05; 1.36]

venous thromboembolism 2.15 [1.61; 2.86]

PE 2.15 [1.41; 3.28]

all cause death 1.01 [0.84; 1.21]

Cv death 1.21 [0.72; 2.02]

all cause death 0.00 [NaN; NaN]

Cv death 0.00 [NaN; NaN]

non fatal MI 0.00 [NaN; NaN]

stroke 0.00 [NaN; NaN]

CV events 0.00 [NaN; NaN]

venous thromboembolism 0.00 [NaN; NaN]

venous thromboembolism 7.31 [2.19; 24.39]

PE 4.98 [1.09; 22.72]

all cause death 1.59 [0.52; 4.87]

Coronary events (CHD) ∞ [NaN; ∞]

Cv death NaN [NaN; NaN]

non fatal MI ∞ [NaN; ∞]

stroke 0.73 [0.37; 1.46]

CV events ∞ [NaN; ∞]

all cause death 0.50 [0.13; 1.97]

Cv death 0.67 [0.11; 3.95]

non fatal MI 0.87 [0.30; 2.49]

stroke 1.01 [0.34; 3.03]

CV events 1.68 [0.41; 6.86]

venous thromboembolism 2.02 [0.19; 21.93]

all cause death 0.77 [0.18; 3.32]

CV events 1.16 [0.64; 2.09]

estrogen alone (0.625 mg of conjugated estrogen per day) (n=100)

vs.

placebo (n=105)

3 arms: 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo

double-blind

Parallel groups

Sample size: 100/105

Primary endpoint: mean minimal coronary-artery diameter

FU duration: 3.6y

0.625 mg/d of conjugated equine estrogen (plus 2.5 mg/d of medroxyprogesterone acetate for women who had not had a hysterectomy) (n=210)

vs.

placebo (n=213)

factorial design of hormone replacement therapy and antioxidant vitamins

double blind

Factorial plan

Sample size: 210/213

Primary endpoint: change in minimum lumen diameter from baseline

FU duration: 2.8 y

micronized 17beta-estradiol alone (n=76)

vs.

placebo (n=76)

3 arms: usual care (control group), estrogen therapy with micronized 17beta-estradiol alone (estrogen group), or 17beta-estradiol plus sequentially administered medroxyprogesterone acetate (estrogen-progestin group)

double blind

Parallel groups

Sample size: 76/76

Primary endpoint: percent stenosis

FU duration: 3.3 y

intravenous followed by oral conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days (n=100)

vs.

placebo (n=99)

3 arms: intravenous followed by oral conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days and placebo

double blind

Parallel groups

Sample size: 100/99

Primary endpoint: number of ischemic episodes

FU duration: 6 months

estradiol +/-medroxyprogesterone (n=44)

vs.

placebo (n=51)

double blind

Parallel groups

Sample size: 44/51

Primary endpoint: angiographic study

FU duration: 33 months

Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily (n=1380)

vs.

placebo (n=1383)

double-blind

Cross over

Sample size: 1380/1383

Primary endpoint: CHD events

FU duration: 4.1 y

micronized 17beta-estradiol (1 mg/d) (n=111)

vs.

placebo (n=111)

double-blind

Parallel groups

Sample size: 111/111

Primary endpoint: intima-media thickness

FU duration: 2 y

2 mg estradiol plus 1 mg norethisterone acetate, 1 tablet daily (n=71)

vs.

placebo (n=69)

double-blind

Parallel groups

Sample size: 71/69

Primary endpoint: recurrent deep venous thrombosis or pulmonary embolism

FU duration: 24 months

transdermal 17 beta-estradiol at a dose of 50 micrograms per 24 h alone for 18 days followed by 10 days of combined treatment with medroxyprogesterone acetate (MPA) 5 mg orally (n=40)

vs.

placebo (n=20)

double-blind

Parallel groups

Sample size: 40/20

Primary endpoint: not defined

FU duration: 1 y

oestradiol valerate 2 mg daily (n=513)

vs.

placebo (n=504)

double-blind

Parallel groups

Sample size: 513/504

Primary endpoint: reinfarction or cardiac death, and all-cause mortality

FU duration: 24 months

estrogen therapy (1 mg of estradiol-17beta per day) (n=337)

vs.

placebo (n=327)

double-blind

Parallel groups

Sample size: 337/327

Primary endpoint: stroke or death

FU duration: 2.8 y

conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n=8506)

vs.

placebo (n=8102)

double-blind

Factorial plan

Sample size: 8506/8102

Primary endpoint: coronary heart disease

FU duration: 5.2 y

oral oestradiol-17beta 1 mg plus norethisterone acetate 0.5 mg daily (n=49)

vs.

placebo (n=51)

double-blind

Parallel groups

Sample size: 49/51

Primary endpoint: not defined

FU duration: 1 y

combined estrogen and progestogen (n=2196)

vs.

placebo (n=2189)

double-blind

Parallel groups

Sample size: 2196/2189

Primary endpoint: major cardiovascular disease, osteoporotic fractures, breast cancer and dementia

FU duration: 11.9 months

estrogen plus medroxyprogesterone acetate ( 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day) (n=104)

vs.

placebo (n=105)

3 arms: 0.625 mg of conjugated estrogen per day, 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate per day, or placebo

double-blind

Parallel groups

Sample size: 104/105

Primary endpoint: mean minimal coronary-artery diameter

FU duration: 3.6y

17 beta-estradiol plus sequentially administered medroxyprogesterone acetate (n=74)

vs.

placebo (n=76)

3 arms: usual care (control group), estrogen therapy with micronized 17beta-estradiol alone (estrogen group), or 17beta-estradiol plus sequentially administered medroxyprogesterone acetate (estrogen-progestin group)

double blind

Sample size: 74/76

Primary endpoint: percent stenosis

FU duration: 3.3 y

intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days (n=94)

vs.

placebo (n=99)

3 arms: intravenous followed by oral conjugated estrogen for 21 days, intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days and placebo

double blind

Parallel groups

Sample size: 94/99

Primary endpoint: number of ischemic episodes

FU duration: 6 months